Resveratrol supplementation improves functional performance in knee osteoarthritis by upregulating sirtuin 1: a randomized study.

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-10-02 DOI:10.1007/s10787-025-01967-9

Asima Karim, Haroon Ahmed Khan, Firdos Ahmad, Rizwan Qaisar

{"title":"Resveratrol supplementation improves functional performance in knee osteoarthritis by upregulating sirtuin 1: a randomized study.","authors":"Asima Karim, Haroon Ahmed Khan, Firdos Ahmad, Rizwan Qaisar","doi":"10.1007/s10787-025-01967-9","DOIUrl":null,"url":null,"abstract":"Purpose: Osteoarthritis (OA) is a debilitating disease of joints. Currently, there are no optimal treatment options to cure OA.Objective: To determine whether resveratrol treatment can improve physical function in knee OA patients. Trial design This investigation employed a single center-based, double-blinded, randomized, placebo-regulated clinical trial structure.Methods: We led a 12-week clinical study involving 137 knee OA patients, aged 63-73. Participants were divided to form a placebo-taking group (n = 70) and an intervention group receiving 500 mg/day of resveratrol (n = 67). Data collection occurred at the start and after 12 weeks. Key study outcomes included: pain intensity (VAS), Oxford Knee Score (OKS), WOMAC index score, knee flexion range of motion (ROM), short physical performance battery (SPPB), handgrip strength (HGS), gait velocity, and levels of SIRT1, C-reactive protein (CRP), and 8-isoprostanes.Results: After accounting for dropouts, 122 patients were analyzed (placebo: n = 65, resveratrol: n = 57). Resveratrol treatment significantly reduced pain intensity and WOMAC scores, while increasing OKS scores, ROM, gait velocity, HGS, and overall SPPB performance (p < 0.05). In addition, OA patients on resveratrol showed higher plasma SIRT1 and lower 8-isoprostanes levels (p < 0.05). The correlation analysis demonstrated robust associations between changes in plasma SIRT1 and improvements in OKS scores (r2 = 0.204, p = 0.0005), SPPB total (r2 = 0.223, p = 0.0001), HGS (r2 = 0.119, p = 0.008), and gait speed (r2 = 0.138, p = 0.004).Conclusion: Overall, resveratrol supplementation enhances the physical capabilities of OA patients by increasing SIRT1 levels. Further research is warranted to more fully define resveratrol's impact on knee OA.Trial registration: This investigation was retrospectively registered on the Open Science Framework (OSF), ensuring transparency and accessibility of the study protocol and outcomes. Registration date (21st April 2025) and URL for protocol ( https://osf.io/registries/my-registrations ).","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01967-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Osteoarthritis (OA) is a debilitating disease of joints. Currently, there are no optimal treatment options to cure OA.

Objective: To determine whether resveratrol treatment can improve physical function in knee OA patients. Trial design This investigation employed a single center-based, double-blinded, randomized, placebo-regulated clinical trial structure.

Methods: We led a 12-week clinical study involving 137 knee OA patients, aged 63-73. Participants were divided to form a placebo-taking group (n = 70) and an intervention group receiving 500 mg/day of resveratrol (n = 67). Data collection occurred at the start and after 12 weeks. Key study outcomes included: pain intensity (VAS), Oxford Knee Score (OKS), WOMAC index score, knee flexion range of motion (ROM), short physical performance battery (SPPB), handgrip strength (HGS), gait velocity, and levels of SIRT1, C-reactive protein (CRP), and 8-isoprostanes.

Results: After accounting for dropouts, 122 patients were analyzed (placebo: n = 65, resveratrol: n = 57). Resveratrol treatment significantly reduced pain intensity and WOMAC scores, while increasing OKS scores, ROM, gait velocity, HGS, and overall SPPB performance (p < 0.05). In addition, OA patients on resveratrol showed higher plasma SIRT1 and lower 8-isoprostanes levels (p < 0.05). The correlation analysis demonstrated robust associations between changes in plasma SIRT1 and improvements in OKS scores (r² = 0.204, p = 0.0005), SPPB total (r² = 0.223, p = 0.0001), HGS (r² = 0.119, p = 0.008), and gait speed (r² = 0.138, p = 0.004).

Conclusion: Overall, resveratrol supplementation enhances the physical capabilities of OA patients by increasing SIRT1 levels. Further research is warranted to more fully define resveratrol's impact on knee OA.

Trial registration: This investigation was retrospectively registered on the Open Science Framework (OSF), ensuring transparency and accessibility of the study protocol and outcomes. Registration date (21st April 2025) and URL for protocol ( https://osf.io/registries/my-registrations ).

查看原文本刊更多论文

补充白藜芦醇通过上调sirtuin 1改善膝关节骨性关节炎的功能表现：一项随机研究。

目的：骨关节炎（OA）是一种使关节衰弱的疾病。目前，没有最佳的治疗方案来治愈OA。目的：探讨白藜芦醇治疗是否能改善膝关节OA患者的身体功能。试验设计本研究采用单中心、双盲、随机、安慰剂调节的临床试验结构。方法：我们领导了一项为期12周的临床研究，涉及137例膝关节OA患者，年龄63-73岁。参与者被分为安慰剂组（n = 70）和干预组（n = 67），每天服用500毫克白藜芦醇。在开始和12周后进行数据收集。主要研究结果包括：疼痛强度（VAS）、牛津膝关节评分（OKS）、WOMAC指数评分、膝关节屈曲活动范围（ROM）、短物理性能电池（SPPB）、握力（HGS）、步态速度、SIRT1、c反应蛋白（CRP）和8-异前列腺素水平。结果：在考虑退出后，分析了122例患者（安慰剂：n = 65，白藜芦醇：n = 57）。白藜芦醇治疗显著降低疼痛强度和WOMAC评分，同时提高OKS评分、ROM、步态速度、HGS和SPPB总体表现（p < 0.05）。此外，服用白藜芦醇的OA患者血浆SIRT1升高，8-异前列腺素水平降低（p < 0.05）。相关分析显示血浆SIRT1的变化与OKS评分（r2 = 0.204, p = 0.0005）、SPPB总分（r2 = 0.223, p = 0.0001）、HGS （r2 = 0.119, p = 0.008）和步态速度（r2 = 0.138, p = 0.004）的改善之间存在显著相关性。结论：总的来说，补充白藜芦醇通过增加SIRT1水平来增强OA患者的身体能力。进一步的研究需要更充分地确定白藜芦醇对膝关节OA的影响。试验注册：本研究在开放科学框架（OSF）上回顾性注册，确保研究方案和结果的透明度和可及性。注册日期（2025年4月21日）和协议URL （https://osf.io/registries/my-registrations）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]